These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 788512)

  • 81. Clinical, epidemiological, and microbiological characteristics of bacteremia caused by high-level gentamicin-resistant Enterococcus faecalis.
    Vigani AG; Oliveira AM; Bratfich OJ; Stucchi RS; Moretti ML
    Braz J Med Biol Res; 2008 Oct; 41(10):890-5. PubMed ID: 19030711
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Coagulation factor protein abundance in the pre-septic state predicts coagulopathic activities that arise during late-stage murine sepsis.
    Heithoff DM; Pimienta G; Mahan SP; Yang WH; Le DT; House JK; Marth JD; Smith JW; Mahan MJ
    EBioMedicine; 2022 Apr; 78():103965. PubMed ID: 35349828
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations.
    Young LS; Martin WJ; Meyer RD; Weinstein RJ; Anderson ET
    Ann Intern Med; 1977 Apr; 86(4):456-71. PubMed ID: 403841
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Use of the antimicrobial removal device prior to blood culture in patients on antibiotic therapy.
    Ringertz S; Eriksson B; Malmborg AS; Nyström S; Wretlind B
    Eur J Clin Microbiol; 1985 Dec; 4(6):544-7. PubMed ID: 4092699
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Achromobacter xylosoxidans bacteremia.
    Manzella JP
    Dig Dis Sci; 1987 Jul; 32(7):781-2. PubMed ID: 3595393
    [No Abstract]   [Full Text] [Related]  

  • 86. A Rare Case of Cedecea Davisae Bacteremia Presenting as Biliary Sepsis.
    Kanakadandi VS; Sarao MS; Cunningham JM
    Cureus; 2019 Aug; 11(8):e5298. PubMed ID: 31579638
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Group VE-2 (Chromobacterium typhiflavum) bacteremia.
    Pien FD
    J Clin Microbiol; 1977 Oct; 6(4):435-6. PubMed ID: 914996
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Serrating through vascular access catheters: a great masquerader with severe systemic manifestations.
    Deliwala SS; Hussain M; Ponnapalli A; Awuah D; McDonald P; Bachuwa G
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33827881
    [No Abstract]   [Full Text] [Related]  

  • 89. Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.
    Lee JY; Kang CI; Ko JH; Lee WJ; Seok HR; Park GE; Cho SY; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6673-6678. PubMed ID: 27572416
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.
    Sullins AK; Abdel-Rahman SM
    Paediatr Drugs; 2013 Apr; 15(2):93-117. PubMed ID: 23529866
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Breakthrough bacteremia and septic shock due to Streptococcus anginosus resistant to daptomycin in a patient receiving daptomycin therapy.
    Palacio F; Lewis JS; Sadkowski L; Echevarria K; Jorgensen JH
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3639-40. PubMed ID: 21502623
    [No Abstract]   [Full Text] [Related]  

  • 92. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis.
    Wong SY; Lee JS; Kwak HK; Via LE; Boshoff HI; Barry CE
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2515-22. PubMed ID: 21444711
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Therapeutic drug monitoring of aminoglycosides in neonates.
    Touw DJ; Westerman EM; Sprij AJ
    Clin Pharmacokinet; 2009; 48(2):71-88. PubMed ID: 19271781
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
    Beringer PM; Vinks AA; Jelliffe RW; Shapiro BJ
    Antimicrob Agents Chemother; 2000 Apr; 44(4):809-13. PubMed ID: 10722474
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Single or multiple daily doses of aminoglycosides: a meta-analysis.
    Barza M; Ioannidis JP; Cappelleri JC; Lau J
    BMJ; 1996 Feb; 312(7027):338-45. PubMed ID: 8611830
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Aminoglycoside dosage regimens. Is once a day enough?
    Hustinx WN; Hoepelman IM
    Clin Pharmacokinet; 1993 Dec; 25(6):427-32. PubMed ID: 8119044
    [No Abstract]   [Full Text] [Related]  

  • 97. The role of schedule of antibiotic therapy on the neutropenic patient.
    Bodey GP; Valdivieso M; Yap BS
    Infection; 1980; Suppl 1():75-81. PubMed ID: 7399718
    [No Abstract]   [Full Text] [Related]  

  • 98. Basis for an adequate dosage of aminoglycoside antibiotics.
    Lüthy R
    Infection; 1980; Suppl 1():58-61. PubMed ID: 7399715
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Antimicrobial chemotherapy - a clinician's viewpoint.
    Lüthy R
    Experientia; 1980 Apr; 36(4):476-9. PubMed ID: 7379929
    [No Abstract]   [Full Text] [Related]  

  • 100. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations.
    Zaske DE; Cipolle RJ; Rotschafer JC; Solem LD; Mosier NR; Strate RG
    Antimicrob Agents Chemother; 1982 Mar; 21(3):407-11. PubMed ID: 7103444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.